JP7827645B2 - 操作されたｔ細胞受容体および使用の方法 - Google Patents

操作されたｔ細胞受容体および使用の方法

Info

Publication number
JP7827645B2
JP7827645B2 JP2022575767A JP2022575767A JP7827645B2 JP 7827645 B2 JP7827645 B2 JP 7827645B2 JP 2022575767 A JP2022575767 A JP 2022575767A JP 2022575767 A JP2022575767 A JP 2022575767A JP 7827645 B2 JP7827645 B2 JP 7827645B2
Authority
JP
Japan
Prior art keywords
tcr
cancer
cell
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022575767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530245A (ja
JP2023530245A5 (https=
JPWO2021252517A5 (https=
Inventor
キャシアン イー
ケ パン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2023530245A publication Critical patent/JP2023530245A/ja
Publication of JP2023530245A5 publication Critical patent/JP2023530245A5/ja
Publication of JPWO2021252517A5 publication Critical patent/JPWO2021252517A5/ja
Application granted granted Critical
Publication of JP7827645B2 publication Critical patent/JP7827645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2022575767A 2020-06-09 2021-06-08 操作されたｔ細胞受容体および使用の方法 Active JP7827645B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036539P 2020-06-09 2020-06-09
US63/036,539 2020-06-09
PCT/US2021/036443 WO2021252517A1 (en) 2020-06-09 2021-06-08 Engineered t cell receptors and methods of use

Publications (4)

Publication Number Publication Date
JP2023530245A JP2023530245A (ja) 2023-07-14
JP2023530245A5 JP2023530245A5 (https=) 2024-06-07
JPWO2021252517A5 JPWO2021252517A5 (https=) 2024-06-07
JP7827645B2 true JP7827645B2 (ja) 2026-03-10

Family

ID=78845879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575767A Active JP7827645B2 (ja) 2020-06-09 2021-06-08 操作されたｔ細胞受容体および使用の方法

Country Status (6)

Country Link
US (1) US20230227526A1 (https=)
EP (1) EP4161555A4 (https=)
JP (1) JP7827645B2 (https=)
CN (1) CN116096740A (https=)
CA (1) CA3186594A1 (https=)
WO (1) WO2021252517A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120718134B (zh) * 2025-08-25 2025-12-26 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017193104A1 (en) 2016-05-06 2017-11-09 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1
WO2019036688A1 (en) 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050010030A1 (en) * 2003-07-02 2005-01-13 Zang Jingwu Z. T cell receptor CDR3 sequence and methods for detecting and treating rheumatoid arthritis
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
IL290655B2 (en) * 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
TW201835100A (zh) * 2017-02-06 2018-10-01 國立研究開發法人國立癌症研究中心 新穎ｔ細胞受體
EP4219543A1 (en) * 2017-11-06 2023-08-02 Immatics Biotechnologies GmbH Novel engineered t cell receptors and immune therapy using the same
AU2019249209A1 (en) * 2018-04-05 2020-10-15 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017193104A1 (en) 2016-05-06 2017-11-09 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1
WO2019036688A1 (en) 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Immunology Immunotherapy，2013年，Vol.62，pp.773-785

Also Published As

Publication number Publication date
EP4161555A4 (en) 2024-06-19
EP4161555A1 (en) 2023-04-12
JP2023530245A (ja) 2023-07-14
CN116096740A (zh) 2023-05-09
CA3186594A1 (en) 2021-12-16
WO2021252517A1 (en) 2021-12-16
US20230227526A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
JP7785696B2 (ja) 操作されたｔ細胞受容体および使用の方法
JP2023548556A (ja) Ｅｇｆｒ抗原を標的とする操作されたｔ細胞受容体および使用方法
JP2024539291A (ja) 神経膠芽腫を治療するための方法および組成物
JP7827645B2 (ja) 操作されたｔ細胞受容体および使用の方法
TWI893070B (zh) 經工程化之t細胞受體及使用方法
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
JP2024539273A (ja) Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
WO2025096983A1 (en) Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
WO2025101705A1 (en) Peptides and engineered t cell receptors targeting a melanoma antigen preferentially expressed in tumors antigen and methods of use
WO2026019786A1 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
CN118302176A (zh) 靶向mage-a4抗原的肽和经改造t细胞受体及使用方法
HK40092477A (zh) 经改造t细胞受体和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260226

R150 Certificate of patent or registration of utility model

Ref document number: 7827645

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150